Developmental Pipeline

Pipeline

Preclinical

Phase 1

Phase 2

Phase 3

High-risk patients with Cardiovascular Disease (CVD), hospitalized with COVID-19

Oral Formulation

more

close

High-risk patients with Cardiovascular Disease (CVD), hospitalized with COVID-19

CardiolRx™

Cardiol has received approval from the U.S. Food and Drug Administration for its Investigational New Drug application to conduct a Phase II/III clinical trial investigating the efficacy and safety of CardiolRx in the treatment of hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease. Learn more…

Acute Myocarditis

Oral Formulation

more

close

Acute Myocarditis

CardiolRx™

Cardiol has completed a Phase I safety and pharmacokinetic study of CardiolRx and is planning an international, multi-center Phase II study to investigate the therapeutic effects of CardiolRx on myocardial recovery in patients with acute myocarditis, a leading cause of sudden cardiac death in people under 35 years of age. Learn more…

Diastolic Heart Failure

Subcutaneous Formulation

more

close

Diastolic Heart Failure

CardiolRx™

The Company is also developing a subcutaneous formulation of CardiolRx to achieve higher bioavailability for the treatment of chronic heart failure.  Heart failure affects over six million people in North America and remains a leading cause of death and hospitalization with associated U.S. healthcare costs exceeding $30 billion annually. Learn more…